Iambic Therapeutics

United States - San Diego, CA

• 06/10/2023
• Series B
• $100,000,000

Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.

Related People

Thomas MillerCo Founder

United States - San Diego, California

Tom Miller is a scientist and entrepreneur with focus on the nexus of AI, chemistry, and biology. He joined the Caltech faculty in 2008 and was promoted to full professor in 2013. He's published more than 130 peer-reviewed articles and patents and received numerous awards for research excellence. In 2020, Tom co-founded and became CEO of Iambic Therapeutics, a technology-driven biopharma that is disrupting the therapeutics landscape with its generative AI drug discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and seasoned drug hunters with strong track records of success in delivering clinically validated breakthrough treatments. The Iambic platform has been demonstrated to deliver high quality, differentiated drugs to clinic with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing an internal pipeline of clinical assets to address unmet patient need across therapeutics areas.

LinkedIn https://www.linkedin.com/in/thomas-miller-322a8521/